Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2000 2
2005 1
2012 1
2013 1
2014 2
2016 1
2019 1
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean valles j[au] (402 results)?
Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
Gomez-Centeno A, Rubio-Romero E, Ovalles JG, Manrique-Arija S, Marsal-Barril S, Amarelo-Ramos J, Del Pino-Montes J, Muñoz-Fernández S, Bustabad S, Barbazán-Álvarez C. Gomez-Centeno A, et al. Among authors: ovalles jg. Rheumatol Int. 2019 Dec;39(12):2015-2024. doi: 10.1007/s00296-019-04378-6. Epub 2019 Aug 8. Rheumatol Int. 2019. PMID: 31396685
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).
Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Del Campo V, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Mouriño-Rodríguez C, Horcada L, Bohórquez C, Montilla C, Salgado E, Díez-Álvarez E, Blanco R, Andreu JL, Fernández-Berrizbeitia O, Expósito L, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Lozano-Rivas N, Bonilla G, Lois Iglesias A, Rubio-Muñoz P, Ovalles J, Tomero E, Boteanu A, Narvaez J, Freire M, Vela P, Quevedo-Vila V, Juan Mas A, Muñoz-Fernández S, Raya E, Moreno M, Velloso-Feijoo ML, Soler G, Vázquez-Rodríguez TR, Pego-Reigosa JM; RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Torrente-Segarra V, et al. Among authors: ovalles j. Semin Arthritis Rheum. 2020 Aug;50(4):657-662. doi: 10.1016/j.semarthrit.2020.05.016. Epub 2020 May 30. Semin Arthritis Rheum. 2020. PMID: 32505871 Free article.
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Riancho-Zarrabeitia L, Martínez-Taboada VM, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Mena Vázquez N, Calvo-Alén J, Menor Almagro R, Tomero Muriel E, Uriarte Isacelaya E, Boteanu A, Andres M, Freire González M, Santos Soler G, Ruiz-Lucea ME, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez J, Expósito L, Hernández Beriaín JA, Horcada L, Aurrecoechea E, Pego Reigosa JM. Riancho-Zarrabeitia L, et al. Among authors: ovalles j. Clin Exp Rheumatol. 2021 May-Jun;39(3):555-563. doi: 10.55563/clinexprheumatol/9kxexc. Epub 2020 Aug 7. Clin Exp Rheumatol. 2021. PMID: 32828148 Free article.
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Riancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, Alonso F, Galindo-Izquierdo M, Ovalles J, Olivé-Marqués A, Fernández-Nebro A, Calvo-Alén J, Menor-Almagro R, Tomero-Muriel E, Uriarte-Isacelaya E, Botenau A, Andres M, Freire-González M, Santos Soler G, Ruiz-Lucea E, Ibáñez-Barceló M, Castellví I, Galisteo C, Quevedo Vila V, Raya E, Narváez-García J, Expósito L, Hernández-Beriaín JA, Horcada L, Aurrecoechea E, Pego-Reigosa JM. Riancho-Zarrabeitia L, et al. Among authors: ovalles j. Lupus. 2020 Oct;29(12):1556-1565. doi: 10.1177/0961203320950477. Epub 2020 Aug 17. Lupus. 2020. PMID: 32807021
Determination of piracetam and its impurities by TLC.
Ovalles JF, Tettey JN, Miller JH, Skellern GG. Ovalles JF, et al. J Pharm Biomed Anal. 2000 Sep;23(4):757-61. doi: 10.1016/s0731-7085(00)00355-1. J Pharm Biomed Anal. 2000. PMID: 10975251 No abstract available.
Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
Ortea I, Roschitzki B, López-Rodríguez R, Tomero EG, Ovalles JG, López-Longo J, de la Torre I, González-Alvaro I, Gómez-Reino JJ, González A. Ortea I, et al. Among authors: ovalles jg. PLoS One. 2016 Apr 6;11(4):e0153140. doi: 10.1371/journal.pone.0153140. eCollection 2016. PLoS One. 2016. PMID: 27050469 Free PMC article.
Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis.
Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, González I, Gómez-Reino JJ, González A. Ortea I, et al. Among authors: ovalles jg. J Proteomics. 2012 Dec 21;77:372-82. doi: 10.1016/j.jprot.2012.09.011. Epub 2012 Sep 20. J Proteomics. 2012. PMID: 23000593 Free article. Clinical Trial.
12 results